{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.0"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"C1 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7793.18","value":"30088.9"},{"groupId":"OG001","spread":"7254.76","value":"43460.0"},{"groupId":"OG002","spread":"15195.76","value":"48350.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5308.95","value":"29933.3"},{"groupId":"OG001","spread":"10445.10","value":"41370.0"},{"groupId":"OG002","spread":"8739.34","value":"40600.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4184.20","value":"19100.0"},{"groupId":"OG001","spread":"9022.35","value":"28350.0"},{"groupId":"OG002","spread":"10192.43","value":"33383.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D1, 24 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4016.24","value":"10310.0"},{"groupId":"OG001","spread":"6392.34","value":"14512.0"},{"groupId":"OG002","spread":"7980.33","value":"22783.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D4, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1740.97","value":"5325.0"},{"groupId":"OG001","spread":"3273.79","value":"6828.0"},{"groupId":"OG002","spread":"7262.77","value":"13208.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C1 D8, ANYTIME SAMPLE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"755.32","value":"1885.0"},{"groupId":"OG001","spread":"859.18","value":"1806.3"},{"groupId":"OG002","spread":"2319.76","value":"3774.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C2 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3108.48","value":"31062.5"},{"groupId":"OG001","spread":"12523.32","value":"40525.0"},{"groupId":"OG002","spread":"20443.90","value":"39195.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"C2 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1129.07","value":"2720.0"},{"groupId":"OG001","spread":"1578.05","value":"3395.0"},{"groupId":"OG002","spread":"3102.85","value":"4235.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C4 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6459.36","value":"32533.3"},{"groupId":"OG001","spread":"21043.21","value":"56550.0"},{"groupId":"OG002","spread":"12470.90","value":"46766.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C4 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"452.55","value":"2700.0"},{"groupId":"OG001","spread":"2578.16","value":"2933.3"},{"groupId":"OG002","spread":"1228.59","value":"3983.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C6 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3818.38","value":"28400.0"},{"groupId":"OG001","spread":"8660.83","value":"48800.0"},{"groupId":"OG002","spread":"3550.12","value":"40366.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"C6 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"148.49","value":"3895.0"},{"groupId":"OG001","spread":"1170.70","value":"4453.3"},{"groupId":"OG002","spread":"1053.59","value":"3385.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"C9 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5868.99","value":"28250.0"},{"groupId":"OG001","spread":"5832.10","value":"34166.7"},{"groupId":"OG002","spread":"16899.85","value":"47050.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"C9 D1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1432.60","value":"1587.0"},{"groupId":"OG001","spread":"5062.88","value":"3580.0"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG002","spread":"NA","value":"2230.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"C12 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8485.28","value":"25600.0"},{"groupId":"OG001","spread":"424.26","value":"39600.0"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG002","spread":"NA","value":"28200.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"C12 D1, END OF INFUSION"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG000","spread":"NA","value":"1450.0"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG001","spread":"NA","value":"6300.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"C18 D1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2353.23","value":"3755.0"},{"groupId":"OG001","spread":"1830.77","value":"1779.8"},{"groupId":"OG002","spread":"4803.09","value":"4576.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"EoT (up to ~ 281 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG002","title":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) population included all participants in the safety population from whom at least one PK sample has been obtained and analysed. The \"0\" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"Predose, end of infusion (EOI), 2 and 24 hours postdose on Cycle (C) 1 Day (D) 1; anytime sample at C1 D4 and D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at end of treatment (EoT, up to approximately 281 weeks.)","title":"DE Phase: Plasma Concentration of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)","type":"SECONDARY","unitOfMeasure":"Nanogram/ millilitre (ng/mL)"}